BrightPath Biotherapeutics Co., Ltd. (4594) Balance sheet
Market cap
¥4.9B
P/E ratio
-3.9x
Brightpath Bio develops novel cancer immunotherapy drugs including cell therapies, antibodies, and personalized vaccines, licensing them to pharmaceutical partners worldwide.
| 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Cash and cash equivalents | - | 824 | 2,555 | 4,951 | 6,529 | 4,901 | 3,018 | 3,265 | 2,305 | 1,531 | 1,057 | 810 | 2,156 |
| Inventories | - | 5 | 13 | 0 | 1 | - | - | - | - | - | - | - | - |
| Total current assets | - | 1,156 | 2,791 | 5,239 | 6,900 | 5,162 | 3,328 | 3,651 | 2,696 | 1,651 | 1,181 | 1,071 | 2,554 |
| Property, plant and equipment, net | - | 45 | 49 | 116 | 266 | 91 | 97 | 48 | 25 | - | - | - | - |
| Total non-current assets | - | 71 | 86 | 169 | 336 | 143 | 146 | 98 | 75 | 50 | 49 | 49 | 51 |
| Total assets | - | 1,227 | 2,877 | 5,408 | 7,236 | 5,304 | 3,475 | 3,749 | 2,771 | 1,701 | 1,230 | 1,121 | 2,605 |
| Total current liabilities | - | 179 | 129 | 161 | 229 | 149 | 173 | 156 | 185 | 77 | 191 | 132 | 161 |
| Total non-current liabilities | - | 24 | 28 | 46 | 56 | 60 | 67 | 55 | 55 | 57 | 60 | 64 | 75 |
| Total liabilities | - | 203 | 157 | 207 | 285 | 208 | 239 | 212 | 240 | 134 | 251 | 196 | 236 |
| Retained earnings | - | -245 | -1,239 | -2,353 | -3,930 | -5,814 | -7,672 | -9,392 | -10,876 | -1,486 | -2,654 | -3,805 | -5,110 |
| Stockholders' equity | 189 | 1,024 | 2,721 | 5,201 | 6,951 | 5,096 | 3,235 | 3,538 | 2,531 | 1,568 | 979 | 925 | 2,368 |